Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
about
The proteasome and proteasome inhibitors in multiple myeloma.Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials.CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myelomaA phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
P2860
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Recent progress in relapsed mu ...... tions for treatment decisions.
@en
type
label
Recent progress in relapsed mu ...... tions for treatment decisions.
@en
prefLabel
Recent progress in relapsed mu ...... tions for treatment decisions.
@en
P2860
P356
P1476
Recent progress in relapsed mu ...... ations for treatment decisions
@en
P2093
Edwin de Wit
P2860
P304
P356
10.1111/BJH.14780
P407
P577
2017-05-30T00:00:00Z